GlassScriptPhysician profile
Gina Chen
NPI 1770322976
$2,279.00
in general payments reported to CMS, 2019-2025
23 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $396 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $298.36 | 2025 | |
| Pfizer INC. | $279.85 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $255.09 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $218.56 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $212.73 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $179.01 | 2024-2025 | |
| Lilly USA, LLC | $128.32 | 2025 | Zepbound, Mounjaro |
| Lundbeck LLC | $103.29 | 2024-2025 | Rexulti, Vyepti |
| Exact Sciences Corporation | $89.12 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $73.99 | 2024-2025 | Evenity, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $63.05 | 2024-2025 | |
| Glaxosmithkline, LLC. | $53.42 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $46.42 | 2024-2025 | Trintellix |
| Medicomp INC | $46.18 | 2024 | Telepatch Cardiac Monitor |
| Astellas Pharma US INC | $42.90 | 2025 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $39.99 | 2024 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $28.42 | 2025 | Opsumit, Uptravi |
| Abbott Laboratories | $26.23 | 2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $21.20 | 2025 | Fanapt |
| Dexcom, INC. | $20.86 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $20.26 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.19 | 2025 | Jardiance |
| Ardelyx, INC. | $14.56 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.